公开(公告)号：US20240425478A1

公开(公告)日：2024-12-26

申请号：US18698664

申请日：2022-10-04

Applicant: Genentech, Inc.

Inventor： Jessica Marie GRANDNER ,  Kevin M. JOHNSON ,  Steven MAGNUSON ,  Jeremy Mark MURRAY ,  Brendan T. PARR ,  Vishal A. VERMA ,  Yong WANG ,  Mingshuo ZENG ,  Melissa A. ASHLEY

IPC: C07D401/12 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/53 ,  A61K31/5377 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14

Abstract: Described here are compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and their use and preparation.

公开(公告)号：US20240228512A1

公开(公告)日：2024-07-11

申请号：US18490736

申请日：2023-10-19

Applicant: Genentech, Inc.

Inventor： Benjamin David RAVETZ ,  Jack Alexander TERRETT ,  BinQing WEI ,  Mingshuo ZENG ,  Cheng SHAO ,  Yinlei SUN

IPC: C07D519/00 ,  A61K31/553 ,  A61P31/00 ,  C07D498/16

CPC classification number: C07D519/00 ,  A61K31/553 ,  A61P31/00 ,  C07D498/16

Abstract: Provided herein are acyclic oxazepinyl compounds comprising a 6-aza moiety that are useful in the treatment of cancers.

公开(公告)号：US20240383897A1

公开(公告)日：2024-11-21

申请号：US18604314

申请日：2024-03-13

Applicant: Genentech, Inc.

Inventor： Elisia VILLEMURE ,  Joachim RUDOLPH ,  Mingshuo ZENG

IPC: C07D471/08 ,  C07D471/10 ,  C07D487/14

Abstract: The present disclosure relates to compounds and salts thereof that are useful for modulating target polypeptides and proteins, in particular BRM. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various BRM-mediated and/or BRG1-mediated diseases or disorders.

公开(公告)号：US20230112485A1

公开(公告)日：2023-04-13

申请号：US17883004

申请日：2022-08-08

Applicant: Genentech, Inc.

Inventor： Elisia VILLEMURE ,  Joachim RUDOLPH ,  Mingshuo ZENG

IPC: C07D471/08 ,  C07D471/10 ,  C07D487/14

Abstract: The present disclosure relates to compounds and salts thereof that are useful for modulating target polypeptides and proteins, in particular BRM. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various BRM-mediated and/or BRG1-mediated diseases or disorders.